Moreover, Igase et al. demonstrated, in a model of hypertensive nephropathy, that the inhibition of AT1 receptors by olmesartan increased plasma levels of Ang-(1-7), leading also to cardio- and renoprotective effects by reducing glomerular sclerosis and renal perivascular collagen deposition [77]. The gene discussed is AGTR1; the disease is glomerulosclerosis.